

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (KL-156) VOLENRELAXIN

PRONUNCIATION voe len" re lax' in

THERAPEUTIC CLAIM To improve cardiovascular, renal and pulmonary functions in patients with heart failure, kidney disease and/or other metabolic dysfunctions

CHEMICAL NAME

Immunoglobulin G, anti-(human serum albumin) (human-Lama glama γ -chain V-D-J region) fusion protein with peptide linker (GGGGQ)₅ fusion protein with 2-29-relaxin 2 (human chain B) fusion protein with peptide linker (GGSGGGSGGG) fusion protein with relaxin 2 (human chain A)

STRUCTURE/SEQUENCE

type	----- location -----	description
bridge	Cys-22 - Cys-96	disulfide bridge
bridge	Cys-161 - Cys-200	disulfide bridge
bridge	Cys-173 - Cys-213	disulfide bridge
bridge	Cys-199 - Cys-204	disulfide bridge

SEQ 1 EVQLLES GGG LVQPGGSLRL SCAASGRYID ETAVAWFRQA PGKGREFVAG
 51 IGGVDITYY ADSVKGRFTI SRDNSKNTLY LQMNSLRPED TAVYYCAARP
 101 GRPLITSKVA DLYPYWGQGT LVTVSSGGGG QGGGGQGGGG QGGGGQGGGG
 151 QSWMEEVIKL CGRELVRAQI AICGMSTWSG GSGGGSGGGQ LYSALANKCC
 201 HVGCTKRSLA RFC

MOLECULAR FORMULA C941 H1475 N281 O295 S11

MOLECULAR WEIGHT 21,797 Da

TRADEMARKS None

SPONSOR Eli Lilly and Company

DESIGNATION CODE LY3540378

CAS REGISTRY NUMBER 2653949-19-8

UNII TVT9XLV5MU

WHO NUMBER 12850

SCS